
Vesicly
Powered by science. Guided by care.
Centered on you.

The Problem

Chronic wounds dramatically affect *quality of life.*

- *‘It’s handicapping and embarrassing’*
- *‘Sitting on a bunch of needles’*
- *‘Cannot sleep’*



The Problem

Chronic skin wounds affect over *250M people.*

Specially those with diabetes, venous insufficency or aging skin.

Vesicly

Phillips CJ , Humphreys I , Fletcher J , Harding K , Chamberlain G , Macey S . Estimating the costs associated with the management of patients with chronic wounds using linked routine data. Int Wound J. 2016;13:1193–1197. https://doi.org/10.1111/iwj.12443.

The Problem

More *access*, less *healthcare spending*

$250B	$20B	$30B	$4B
Globally	Latin America	USA	Argentina


→ 5x **longer** hospital stays → Months of treatment, **intensive care**

The Solution

At Vesicly, we are developing exosome-based products to restore the body's *regenerative capacity.*

Vesicly

But before we start: Exosomes




Exosomes are tiny powerhouses of cellular communication and *hold immense potential for revolutionizing* cosmetics, healthcare, and pharmaceutical research.

They are Cellular Therapy 2.0. Bringing the same cell effect without the drawbacks.


Vesicly

Technology

Bioprintable patches with exosomes for wound *healing*



We take exosomes from stem cells



Mix them with hydrogel



And then 3D print the patch

Technology Platform

Our proprietary *end-to-end* system

1

Production:
High-yield
3D culture

2

Purification:
Breakthrough
isolation method

3

Formulation:
Off-the-shelf
stability

Market Opportunity

Why *now?*

Total Addressable Market (TAM)

$25B

Global chronic wound care market

Serviceable Addressable Market (SAM)

$3B

Advanced wound care & initial target markets

Serviceable Obtainable Market (SOM)

$150M

Early revenue from EaaS + initial patch adoption

Business Model

Two phases, one *vision*

1

B2B *Service*

Exosomes as a Service

Biotech – Pharma – Cosmetics

2

B2B *Medical Device*

Patch

Hospitals – Wound care clinics

Traction & GTM

Go-to-market *strategy*

Exosomes as a Service | Now – 12 months

Focus: EaaS & Cosmetic Ingredients

Patch | 1 – 3 years

Focus: Medical device & therapeutics.

Our Competition



Science, operations *& vision*



Mikele Amondarain, Ph.D

CEO & Co-Founder



Carlos Luzzani, Ph.D.

COO & Co-Founder

Advisors



Ana Rovetta, Ph.D

R&D The Chemist Look



José Luis Pedraz, Ph.D

NanoBioCel

Traction

Demand *before* launch

+1000

inbound requests

from patients, families and caregivers

+50

healthcare professionals

engaged with us to know more about the product

From Traction to Scale

2025

- Provisional patent filed US 63/904,174
- +10 LOIs signed

2026

- 1 paid pilot secured
- 4+ paid pilots in negotiation
- Second patent in development

2027

- Initial EaaS revenue
- GMP-production
- Regulatory strategy


2028-2029

- First in human
- Expand to other tissues

Trusted by:

The Ask

Pre-seed round: $500K





Imagine a world where our body don't lose its *vitality* with the pass of time.

Mikele Amondarain
mikele@vesicly.com
LinkedIn: Mikele Amondarain

Carlos Luzzani
charlie@vesicly.com
LinkedIn: Carlos Luzzani

Thank you for your time.